NCT04238624进行中（未招募）2 期
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 16
- 试验地点
- 13
- 主要终点
- Overall Response Rate per RECIST 1.1 Criteria
研究概览
简要总结
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •* Pathological (histologically or cytologically) proven diagnosis of BRAF-V600E mutant ATC (a diagnosis that is noted to be consistent with ATC is acceptable)
- •* Either Metastatic disease or locoregional disease that is considered not resectable for cure
- •* Ideally a surgeon should determine that the disease is not resectable for cure, but this can also be done by any investigator
- •* Patients must have measurable disease according to RECIST 1.1 criteria, defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded for nonnodal lesions and short axis for nodal lesions) as \>/= 20 mm with conventional techniques or as \>/= 10 mm with spiral CT scan, MRI, or calipers by clinical exam
- •* Age \>/= 18 years
- •* Eastern Cooperative Oncology Group (ECOG) performance status \/= 60)
- •* Able to swallow and retain orally administered medication
- •* Patient must have normal organ and marrow function as defined below:
- •* Absolute neutrophil count \>/=1.5 x 10\^9/L
- •* Hemoglobin \>/=8 g/dL
- •* Platelets \>/=100 x 10\^9/L
- •* Serum bilirubin \/=50 mL/min or 24-h urine creatinine clearance \>/=50 mL/min
- •* Left ventricular ejection fraction greater than or equal to instutional lower limit of normal (LLN) by echocardiogram or multigated acquisition (MUGA)
- •* Negative pregnancy test (serum or urine) within 14 days of registration for women of childbearing potential. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) before study entry and for the duration of study participation. Men treated or enrolled on this protocol must also agree to use adequate contraception before the study, for the duration of study participation, and for 4 months after completion of trametinib administration
- •* Must agree to allow 2-4 separate biopsies of any malignant lesion. For patients whose biopsies (initial) are deemed as unsafe or contraindicated, they will not be eligible.
- •* Ability to understand and willingness to sign a written informed consent document. Note: Use of Legally Authorized Representative (LAR) is permitted
排除标准
- •* Previous documentation or current evidence of treatment with dabrafenib and trametinib.
- •° Exception: (1) Patients who started dabrafenib and tranetinib for ATC at an institution outside of MSK are eligible or (2) with the consent of the PI (Sherman). However, this exception is limited to 8 subjects.
- •* Active brain metastases, unless an exception is granted by the Principal Investigator.
- •* Current interstitial lung disease or pneumonitis
- •* Prior history of idelalisib therapy. Exceptions allowed with the consent of the principal investigator (Dr. Sherman)
- •* History of retinal vein occlusion (RVO) or central serous retinopathy (CSR):
- •° History of RVO or CSR or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension)
- •* History or current evidence of cardiovascular risk, including any of the following:
- •* Left ventricular ejection fraction (LVEF) \/=480msec
- •* Current evidence of clinically significant uncontrolled arrhythmias (exception: patients with controlled atrial fibrillation for \>30 days before enrollment are eligible)
- •* History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months before treatment
- •* Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)
- •HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with trametinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy
- •* Uncontrolled intercurrent illness that would limit compliance with study requirement.
- •* Inability to receive immunotherapy for the following reasons:
- •* Any prior grade \>/=3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent or any unresolved irAE grade \>1
- •* Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Exceptions allowed with the consent of the principal investigator (Dr. Sherman)
- •* Active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- •* History of primary immunodeficiency
- •* History of allogeneic organ transplant
- •* Known history of previous clinical diagnosis of active tuberculosis (this does not include a history of being PPD positive)
研究组 & 干预措施
BRAF-mutant ATC
Experimental
Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
干预措施: Trametinib (Drug)
BRAF-mutant ATC
Experimental
Participants will have a diagnosis of BRAF-V600E mutant Anaplastic Thyroid Cancer
干预措施: Dabrafenib (Drug)
结局指标
主要结局
Overall Response Rate per RECIST 1.1 Criteria
时间窗: 2 years
Response and progression will be evaluated by using criteria proposed in RECIST 1.1.
次要结局
未报告次要终点
研究者
研究点 (13)
Loading locations...
相似试验
招募中
2 期
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT06699602Memorial Sloan Kettering Cancer Center10
招募中
1 期
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLLymphomaPrimary Central Nervous System LymphomaNCT06475235Dana-Farber Cancer Institute15
招募中
1 期
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck CancerHead and Neck CancerHead CancerHead Cancer NeckNeck CancerHead and Neck Squamous Cell CarcinomaHNSCCNCT04722523Memorial Sloan Kettering Cancer Center40
Unknown
1 期
Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract CancerCholangiocarcinomaNCT03943043Istituto Clinico Humanitas85
进行中（未招募）
2 期
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell CarcinomaMetastatic Oral Cavity Squamous Cell CarcinomaMetastatic Oropharyngeal Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaSquamous Cell Carcinoma of Unknown PrimaryNCT04862650Marcelo Bonomi46